JPH10226615A - Composition containing aspartic acid-phenylalanine cyclic dipeptide derivative - Google Patents

Composition containing aspartic acid-phenylalanine cyclic dipeptide derivative

Info

Publication number
JPH10226615A
JPH10226615A JP9049686A JP4968697A JPH10226615A JP H10226615 A JPH10226615 A JP H10226615A JP 9049686 A JP9049686 A JP 9049686A JP 4968697 A JP4968697 A JP 4968697A JP H10226615 A JPH10226615 A JP H10226615A
Authority
JP
Japan
Prior art keywords
compound
composition
general formula
present
phenylalanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9049686A
Other languages
Japanese (ja)
Inventor
Kenji Hanabusa
謙二 英
Toru Miki
徹 三木
Hiroyoshi Shirai
汪芳 白井
Koichi Iyanagi
宏一 井柳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Chemical Industries Inc
Original Assignee
Pola Chemical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Chemical Industries Inc filed Critical Pola Chemical Industries Inc
Priority to JP9049686A priority Critical patent/JPH10226615A/en
Publication of JPH10226615A publication Critical patent/JPH10226615A/en
Pending legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain the subject cyclic dipeptide-containing composition that can improve stability of medicines, cosmetics, food products and the like, particularly their stability at a temperature near the body temperature by admixing a specific compound to these products. SOLUTION: 1,3,5-Benzenetricarboxylic acid having the stereostructure responding to the compound to be prepared is allowed to react with thionyl chloride and the resultant acid chloride is allowed to react with the corresponding alkylamine or alkenylamine, and the product is purified, when necessary, to form an aspartic acid-phenylalanine cyclic dipeptide derivative of formula I [R is a 8-22C (cyclic structure-including) straight or branched alkyl or alkenyl] typically cyclo(L-β-dimethyloctylasparaginyl-L-phenylalanine). This compound is admixed to cosmetics, medicines and the like, particularly of high content of oily components. The amount of the compound of formula I is preferably 0.1-100 pts.wt. per 1 pt.wt. of the oily component.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明が属する技術分野】本発明は、オイル等の流動性
有機物の増粘・ゲル化に好適なアスパラギン酸フェニル
アラニン環状ジペプタイド誘導体を含有する組成物に関
する。
The present invention relates to a composition containing a phenylalanine aspartate cyclic dipeptide derivative suitable for thickening and gelling a fluid organic substance such as oil.

【0002】[0002]

【従来の技術】化粧品、医薬品、食品などの分野で、そ
れらの製剤の粘度や硬度を高くすることは安定性を確保
する意味で非常に重要なことであった。この様な硬度や
粘度を高める手段としては、増粘剤を用いる方法やワッ
クス等のワックス構造を利用する方法がある。しかしな
がら、増粘剤はアルキルアクリレートコポリマー等の水
溶性のものが知られているのみであり、坐剤やリップカ
ラー等のオイルゲル系には適用しにくかった。ワックス
の構造を利用する方法では、ワックスのつくる構造が温
度に対して弱いため、40℃付近の体温域で安定性を向
上するためにはワックス量が多くなりすぎ、のびが重
い、化粧料がムラづきする、肛門などに挿入すると痛か
ったり、異物感がひどい等と使用性を損なうことが少な
くなかった。又、有機成分のゲル化剤として12−ヒド
ロキシステアリン酸が知られているが、このものはゲル
を形成するか溶液になるかの何れかの状態しか提供でき
ず、粘度をコントロール事が困難であった。即ち、使用
性を損なうことなく、体温付近の温度で系を安定化する
手段が求められていた。
2. Description of the Related Art In the fields of cosmetics, pharmaceuticals, foods and the like, increasing the viscosity and hardness of these preparations has been very important in terms of ensuring stability. As means for increasing the hardness or viscosity, there are a method using a thickener and a method using a wax structure such as wax. However, only water-soluble thickeners such as alkyl acrylate copolymers are known, and it has been difficult to apply them to oil gel systems such as suppositories and lip colors. In the method using the structure of the wax, the structure of the wax is weak against the temperature, so the amount of the wax is too large to improve the stability in the body temperature region around 40 ° C. In many cases, the usability was impaired because of unevenness, pain when inserted into the anus, etc., and severe foreign body sensation. Also, 12-hydroxystearic acid is known as a gelling agent for an organic component, but it can provide only a state of forming a gel or becoming a solution, and it is difficult to control viscosity. there were. That is, there has been a demand for means for stabilizing the system at a temperature near body temperature without impairing usability.

【0003】一方、後記一般式(I)に表される化合物
は既知の化合物であって、これらの化合物が流動性を有
する有機物質に対してゲル化作用を発揮することは知ら
れていたが、化粧料や医薬に含有させると、その安定性
が向上しうることは全く知られていない。
On the other hand, compounds represented by the following general formula (I) are known compounds, and it has been known that these compounds exert a gelling effect on organic substances having fluidity. It is not known at all that the stability can be improved by incorporating it into cosmetics or medicines.

【0004】[0004]

【発明が解決しようとする課題】本発明はこの様な状況
下に為されたものであって、安定性取り分け40℃付近
の高温における安定性に優れた医薬品、化粧品、食品等
の組成物を提供することを課題とする。
DISCLOSURE OF THE INVENTION The present invention has been made under such a circumstance, and is intended to provide a composition for pharmaceuticals, cosmetics, foods and the like which has excellent stability especially at a high temperature of about 40 ° C. The task is to provide.

【0005】[0005]

【課題を解決するための手段】本発明者らはこの様な状
況に鑑み、化粧料や医薬など油性成分を含有する組成物
の体温付近の温度(40℃付近)に於ける安定性を、使
用感を損なうことなく向上させる手段を求めて鋭意研究
を重ねた結果、次に示す一般式(I)に表される化合物
群がその様な性質を有していることを見いだした。更に
これを医薬品、化粧品、食品等の組成物に配合すること
により組成物の体温付近の温度における安定性を向上さ
せることを見いだした。更に検討を重ねた結果、粘度の
温度に対する変化が少なく、5〜10℃でかかる組成物
を使用しても使用性を損なわないことを見いだし発明を
完成させるに至った。以下、本発明について発明の実施
の形態を中心に詳細に説明する。
In view of such circumstances, the present inventors have studied the stability of a composition containing an oily component such as a cosmetic or a medicine at a temperature near body temperature (around 40 ° C.). As a result of intensive studies in search of means for improving the usability without impairing usability, it has been found that the compounds represented by the following general formula (I) have such properties. Furthermore, it has been found that the stability of the composition at a temperature near the body temperature is improved by blending it with a composition such as a medicine, cosmetics, and food. As a result of further studies, they have found that there is little change in viscosity with respect to temperature and that use of such a composition at 5 to 10 ° C. does not impair the usability, and has completed the invention. Hereinafter, the present invention will be described in detail focusing on embodiments of the invention.

【0006】[0006]

【化6】 一般式(I) (但し、Rは炭素数8〜22の環状構造を含むことので
きる直鎖又は分岐のアルキル基又はアルケニル基を表
す。)
Embedded image General formula (I) (where R represents a linear or branched alkyl group or alkenyl group that can have a cyclic structure having 8 to 22 carbon atoms)

【0007】[0007]

【発明の実施の形態】BEST MODE FOR CARRYING OUT THE INVENTION

(1)本発明の組成物に含有される一般式(I)に表さ
れる化合物 本発明の組成物に含有される化合物は上記一般式(I)
に表される構造を有する。これらの内、特に好ましい物
は一般式(II)に表される環状部分がL,Lの立体構
造を有する物である。この様な化合物の好ましい例とし
ては、例えば、シクロ(L−β−ジメチルオクチルアス
パラギニル−L−フェニルアラニル)(化合物1)、シ
クロ(L−β−ラウリルアスパラギニル−L−フェニル
アラニル)(化合物2)、シクロ(L−β−ステアリル
アスパラギニル−L−フェニルアラニル)(化合物
3)、シクロ(L−β−オレイルアスパラギニル−L−
フェニルアラニル)(化合物4)、、シクロ(L−β−
イソオクチルアスパラギニル−L−フェニルアラニル)
(化合物5)又はシクロ(L−β−シクロヘキシルアス
パラギニル−L−フェニルアラニル)(化合物5)等が
挙げることができる。これらの内、特に好ましいもの
は、化合物1〜3である。
(1) Compound represented by the general formula (I) contained in the composition of the present invention The compound contained in the composition of the present invention is represented by the above general formula (I)
Has a structure represented by Among these, a particularly preferred one is one in which the cyclic portion represented by the general formula (II) has an L, L steric structure. Preferred examples of such a compound include, for example, cyclo (L-β-dimethyloctylasparaginyl-L-phenylalanyl) (compound 1), cyclo (L-β-laurylasparaginyl-L-phenylarayl) Nil) (compound 2), cyclo (L-β-stearylasparaginyl-L-phenylalanyl) (compound 3), cyclo (L-β-oleylasparaginyl-L-
Phenylalanyl) (compound 4), cyclo (L-β-
Isooctyl asparaginyl-L-phenylalanyl)
(Compound 5) or cyclo (L-β-cyclohexylasparaginyl-L-phenylalanyl) (Compound 5). Of these, compounds 1 to 3 are particularly preferred.

【0008】[0008]

【化7】 一般式(II) (但し、Rは炭素数8〜22の環状構造を含むことので
きる直鎖又は分岐のアルキル基又はアルケニル基を表
す。)
Embedded image General formula (II) (where R represents a linear or branched alkyl group or alkenyl group that can have a cyclic structure having 8 to 22 carbon atoms)

【0009】[0009]

【化8】 化合物1Embedded image Compound 1

【0010】[0010]

【化9】 化合物2Embedded image Compound 2

【0011】[0011]

【化10】 化合物3Embedded image Compound 3

【0012】[0012]

【化11】 化合物4Embedded image Compound 4

【0013】[0013]

【化12】 化合物5Embedded image Compound 5

【0014】[0014]

【化13】 化合物6Embedded image Compound 6

【0015】本発明の化合物は何れも既知の化合物よ
り、製造することができる。これらの化合物は例えば次
に示す方法で製造すればよい。即ち、対応する立体構造
を有する1,3,5−ベンゼントリカルボン酸に塩化チ
オニルを反応させて酸クロライドと為し、これと対応す
るアルキルアミン又はアルケニルアミンを反応させれば
よい。この反応の生成物は再結晶やカラムクロマトグラ
フィー等の通常の精製手段で精製することができる。
All of the compounds of the present invention can be prepared from known compounds. These compounds may be produced, for example, by the following method. That is, 1,3,5-benzenetricarboxylic acid having a corresponding steric structure may be reacted with thionyl chloride to form an acid chloride, which may be reacted with the corresponding alkylamine or alkenylamine. The product of this reaction can be purified by ordinary purification means such as recrystallization and column chromatography.

【0016】<製造例1> 化合物1の合成 アスパルテーム1.6gとp−トルエンスルホン酸の触
媒量と3,7−ジメチルオクタノール40mlとを減圧
下4時間160℃で加熱した。この反応物に石油エーテ
ル300mlを加え抽出し、濾過して12時間室温に放
置し、析出物を集めた。元素分析値(N:6.76%、
C:68.51%、O:8.45%)及び赤外吸光スペ
クトル(3192、1742、1675cm-1)より、
その構造が化合物1と確認された。収量1.54g、収
率63%
<Production Example 1> Synthesis of Compound 1 1.6 g of aspartame, a catalytic amount of p-toluenesulfonic acid and 40 ml of 3,7-dimethyloctanol were heated at 160 ° C. under reduced pressure for 4 hours. The reaction product was extracted by adding 300 ml of petroleum ether, filtered, and allowed to stand at room temperature for 12 hours to collect a precipitate. Elemental analysis value (N: 6.76%,
C: 68.51%, O: 8.45%) and infrared absorption spectrum (3192, 1742, 1675 cm -1 )
Its structure was identified as compound 1. 1.54 g, 63% yield

【0017】<製造例2> 化合物2の合成 製造例1の3,7−ジメチルオクタノールをラウリルア
ルコールに変え、同様に処理して収率54%で化合物2
を得た。
<Preparation Example 2> Synthesis of Compound 2 Compound 3, was prepared in the same manner as in Preparation Example 1 except that 3,7-dimethyloctanol was changed to lauryl alcohol, and the same treatment was carried out in a yield of 54%.
I got

【0018】<製造例3> 化合物3の合成 製造例2のラウリルアルコールをステアリルアルコール
に変えて同様に操作し、収率61%で化合物3を得た。
<Production Example 3> Synthesis of Compound 3 The same operation was carried out except that lauryl alcohol in Production Example 2 was changed to stearyl alcohol, to obtain Compound 3 in a yield of 61%.

【0019】<製造例4> 化合物4の合成 製造例2のラウリルアルコールをオレイルアルコールに
変えて同様に操作し、収率46%で化合物4を得た。
<Production Example 4> Synthesis of Compound 4 The same operation was carried out except that lauryl alcohol in Production Example 2 was replaced with oleyl alcohol, to obtain Compound 4 in a yield of 46%.

【0020】<製造例5> 化合物5の合成 製造例2のラウリルアルコールを2−エチルヘキシルア
ルコールに変えて同様に操作し、収率52%で化合物5
を得た。
<Production Example 5> Synthesis of Compound 5 The same operation was carried out except that lauryl alcohol of Production Example 2 was changed to 2-ethylhexyl alcohol, and Compound 5 was obtained in a yield of 52%.
I got

【0021】<製造例6> 化合物6の合成 製造例2のラウリルアルコールをシクロヘキシルアルコ
ールに変えて同様に操作し、収率55%で化合物6を得
た。
<Production Example 6> Synthesis of Compound 6 The same operation was carried out except that lauryl alcohol in Production Example 2 was replaced with cyclohexyl alcohol, to obtain Compound 6 in a yield of 55%.

【0022】かくして得られた本発明の組成物に含有さ
れる化合物は何れも流動性を有する有機物質乃至は組成
物を増粘及び/又はゲル化させる作用に優れる。この作
用により、医薬品、化粧料、食品などの組成物を安定化
することができる。この作用は40℃付近の高温域でも
同様に観測される。本発明を用いて有機物質乃至は組成
物を増粘及び/又はゲル化させるには、当該有機物質乃
至は組成物1重量部に対して0.1〜100重量部、よ
り好ましくは0.5〜90重量部、更に好ましくは1〜
80重量部を加え加熱して相溶させれば良い。この場
合、本発明の化合物は唯1種のみを用いても良いし2種
以上を用いても良い。本発明の化合物が増粘及び/又は
ゲル化しうる有機物質としては、例えば、四塩化炭素、
テトラヒドロフラン、ヘキサン、シクロヘキサン、ベン
ゼン、トルエン、クロロベンゼン、ピリジン等のような
有機溶剤類、ケロシン、ガソリン、軽油、重油等の燃
料、オリーブ油、大豆油、コーン油、ヒマシ油、牛脂、
ホホバ油等の動植物油、スクワラン、流動パラフィン等
の鉱物油、ジメチルポリシロキサンやメチルフェニルポ
リシロキサン等のシリコーン類、オレイン酸オクチルド
デシル、グリセリルトリイソオクタネート、ネオペンチ
ルグリコールジイソオクタネート等の合成エステル類が
例示できる。これらの内、本化合物は従来ではゲル化さ
せ難かった流動パラフィンやスクワラン等の炭化水素類
や環状ジメチルシリコーンやジメチコン等をゲル化しう
る。従って、これらの成分を含有する化粧料や医薬の安
定化に本化合物は好適に用いられる。更にペイント、食
品等も一般式(I)に表される化合物を含有させて安定
化させることのできる組成物として例示できる。下記に
増粘・ゲル化作用を試験例として示す。
Each of the compounds contained in the composition of the present invention thus obtained is excellent in the action of thickening and / or gelling the organic substance having fluidity or the composition. This action can stabilize compositions such as pharmaceuticals, cosmetics, and foods. This effect is also observed in a high temperature range around 40 ° C. In order to thicken and / or gel the organic substance or the composition using the present invention, 0.1 to 100 parts by weight, more preferably 0.5 part by weight, per 1 part by weight of the organic substance or the composition is used. -90 parts by weight, more preferably 1-
80 parts by weight may be added and heated to make them compatible. In this case, only one compound of the present invention may be used, or two or more compounds may be used. Examples of the organic substance capable of thickening and / or gelling the compound of the present invention include, for example, carbon tetrachloride,
Organic solvents such as tetrahydrofuran, hexane, cyclohexane, benzene, toluene, chlorobenzene, pyridine, etc., fuels such as kerosene, gasoline, light oil, heavy oil, olive oil, soybean oil, corn oil, castor oil, beef tallow,
Synthesis of animal and vegetable oils such as jojoba oil, mineral oils such as squalane, liquid paraffin, silicones such as dimethylpolysiloxane and methylphenylpolysiloxane, octyldodecyl oleate, glyceryl triisooctanoate, neopentyl glycol diisooctate, etc. Esters can be exemplified. Of these, the present compound can gel hydrocarbons such as liquid paraffin and squalane, cyclic dimethyl silicone, dimethicone, and the like, which were conventionally difficult to gel. Therefore, the present compound is suitably used for stabilizing cosmetics and medicines containing these components. Further, paints, foods, and the like can also be exemplified as compositions that can be stabilized by containing the compound represented by the general formula (I). The thickening / gelling action is shown below as test examples.

【0023】<試験例> 増粘・ゲル化作用 試験管に各種有機成分を1cm3秤りとり、これに上記
化合物の最も好ましい代表例である、化合物1を用いて
ゲル化作用を検討した。即ち、適当量の化合物1を加え
混合し、相溶するまで加熱攪拌した。相溶したものを2
5℃まで冷却し、ゲル化しているか否かを肉眼で判定し
た。結果を表1に示す。化合物1は何れの有機物質に対
してもゲル化する作用に優れることが判る。
<Test Example> Thickening / Gelling Action Various organic components of 1 cm 3 were weighed in a test tube, and the gelling action was examined using Compound 1, which is the most preferable representative example of the above compound. That is, an appropriate amount of Compound 1 was added, mixed, and heated and stirred until they were compatible. What was compatible 2
After cooling to 5 ° C., it was visually determined whether or not the gel was formed. Table 1 shows the results. It can be seen that Compound 1 has an excellent gelling effect on any organic substance.

【0024】[0024]

【表1】 [Table 1]

【0025】(2)本発明の組成物 本発明の組成物は上記一般式(I)に表される化合物を
含有することを特徴とする。本発明の組成物としては、
例えば、医薬、化粧料、食品等が例示できる。これらの
組成物では、化粧料と医薬が好ましく、更に化粧料と医
薬の中でも油性成分を多く含むもので、例えばオイルゲ
ル製品、油中水乳化製品などが例示できる。具体的な好
ましい例としては、例えば医薬であれば、坐剤、油中水
乳化皮膚外用剤、リピッド製剤、リポソーム製剤等が例
示でき、化粧料であればリップカラー、アイライナー、
リップクリーム、ファンデーション等のオイルゲル製
品、マニュキア、ペディキュア、ネイルコート等の含有
機溶剤製剤、クリーム、ファンデーション等の油剤含有
量が多い乳化製剤などが例示でき、食品としては、チョ
コレート、バター、マーガリン等の油脂製品などが例示
できる。勿論、クレヨン、鉛筆等の文房具やシーリング
剤等のような建設用品に応用することも可能であり、こ
れらも本発明の組成物の範囲にある。
(2) Composition of the Present Invention The composition of the present invention is characterized by containing the compound represented by the above general formula (I). As the composition of the present invention,
For example, medicines, cosmetics, foods and the like can be exemplified. In these compositions, cosmetics and medicaments are preferable, and among these cosmetics and medicaments, oily components are included in a large amount, and examples thereof include oil gel products and water-in-oil emulsion products. Specific preferred examples include, for example, pharmaceuticals, suppositories, water-in-oil emulsified skin external preparations, lipid preparations, liposome preparations, and the like, and cosmetics such as lip colors, eyeliners, and the like.
Oil gel products such as lip balms, foundations, etc., can be exemplified, for example, emulsified formulations having a large oil content such as manicure, pedicure, nail coat, etc., creams, foundations, etc. Fat products and the like can be exemplified. Of course, it is also possible to apply to stationery such as crayon, pencil and the like and construction supplies such as sealing agents and the like, which are also within the scope of the composition of the present invention.

【0026】本発明の組成物における一般式(I)に表
される化合物の好ましい含有量は、増粘作用が期待でき
る量であれば良く、従って、油性成分1重量部に対して
0.1〜100重量部、より好ましくは0.5〜90重
量部、更に好ましくは1〜80重量部であり、組成物全
体に対しては0.01〜20重量%であり、よりに好ま
しくは0.05〜18重量%であり、更に好ましくは
0.1〜16重量%である。本発明の組成物に於いて
は、一般式(I)に表される化合物は唯1種を含有させ
ても良いし、2種以上を組み合わせて含有させても良
い。本発明の組成物に於いては、上記一般式(I)に表
される化合物以外に、これら組成物で用いられている任
意成分を含有することができる。かかる任意成分として
は、例えば、ワセリンやマイクロクリスタリンワックス
等のような炭化水素類、ホホバ油やゲイロウ等のエステ
ル類、牛脂、オリーブ油等のトリグリセライド類、セタ
ノール、オレイルアルコール等の高級アルコール類、ス
テアリン酸、オレイン酸等の脂肪酸、グリセリンや1,
3−ブタンジオール等の多価アルコール類、非イオン界
面活性剤、アニオン界面活性剤、カチオン界面活性剤、
両性界面活性剤、エタノール、カーボポール等の増粘
剤、防腐剤、紫外線吸収剤、抗酸化剤、色素、粉体類、
甘味剤、酸味剤等が例示できる。本発明の組成物は一般
式(I)に表される化合物によって40℃付近の体温域
でも安定であり、更に5〜10℃でも使用性を損なわな
い。
The preferred content of the compound represented by the general formula (I) in the composition of the present invention is not particularly limited as long as a thickening effect can be expected. To 100 parts by weight, more preferably 0.5 to 90 parts by weight, still more preferably 1 to 80 parts by weight, 0.01 to 20% by weight, more preferably 0.1 to 20% by weight, based on the whole composition. It is from 0.05 to 18% by weight, more preferably from 0.1 to 16% by weight. In the composition of the present invention, the compound represented by the general formula (I) may contain only one kind or a combination of two or more kinds. The compositions of the present invention may contain, in addition to the compound represented by the general formula (I), optional components used in these compositions. Such optional components include, for example, hydrocarbons such as petrolatum and microcrystalline wax, esters such as jojoba oil and gay wax, triglycerides such as tallow, olive oil, higher alcohols such as cetanol and oleyl alcohol, and stearic acid. , Fatty acids such as oleic acid, glycerin and 1,
Polyhydric alcohols such as 3-butanediol, nonionic surfactants, anionic surfactants, cationic surfactants,
Amphoteric surfactants, thickeners such as ethanol and carbopol, preservatives, ultraviolet absorbers, antioxidants, pigments, powders,
Sweetening agents, sour agents and the like can be exemplified. The composition of the present invention is stable even in a body temperature range around 40 ° C. by the compound represented by the general formula (I), and does not impair the usability even at 5 to 10 ° C.

【実施例】以下に実施例を示して本発明について更に詳
細に説明するが、本発明がこれら実施例にのみ限定を受
けないことは言うまでもない。
The present invention will be described in more detail with reference to the following examples, but it goes without saying that the present invention is not limited to these examples.

【0027】<実施例1〜4> 配合例 下記の表2に示す処方に従ってファンデーションを作成
した。即ち粉体成分をヘンシェルミキサーで混合した
後、パルベライザーで粉砕し、これをダブルプラネタリ
ーミキサーに入れその他の成分を溶解して加え、加熱し
ながら混練りし金皿に詰め加熱プレスしファンデーショ
ンを得た。併せて、このものを40℃に3カ月保存した
場合の観察結果を示した。本発明の組成物は安定性を向
上していることが判る。尚、評価基準は++:著しい、
+:明らかに観察できる、±:僅かに見られる、−:全
く見られないであった。又、5℃における使用性も専門
パネラーにより評価してもらった。結果をあわせて表2
に示す。本発明の組成物は低温での使用性も良いことが
判る。
Examples 1-4 Formulation Examples A foundation was prepared according to the formulation shown in Table 2 below. That is, after mixing the powder components with a Henschel mixer, pulverizing with a pulverizer, putting this in a double planetary mixer, dissolving and adding the other components, kneading while heating, filling in a metal plate, heating and pressing to obtain a foundation. Was. In addition, the results of observation when this was stored at 40 ° C. for 3 months are shown. It can be seen that the composition of the present invention has improved stability. The evaluation criteria are ++: remarkable,
+: Clearly observable, ±: slightly observed,-: not observed at all. The usability at 5 ° C. was also evaluated by a specialized panel. Table 2 with the results
Shown in It turns out that the composition of the present invention has good usability at low temperatures.

【0028】[0028]

【表2】 [Table 2]

【0029】<実施例5〜8>表3に示す処方に従って
クリームを作成した。即ち、ア、イ、ウ、エをそれぞれ
80℃で加熱溶解又は分散し、アとイを混練りし、これ
をウで希釈し、更にエを徐々に加え乳化した。これを攪
拌冷却しクリームを得た。併せて、このものを40℃に
3カ月保存した場合の観察結果を示した。本発明の組成
物は安定性を向上していることが判る。尚、評価基準は
++:著しい、+:明らかに観察できる、±:僅かに見
られる、−:全く見られないであった。又、5℃におけ
る使用性も専門パネラーにより評価してもらった。結果
をあわせて表3に示す。本発明の組成物は低温での使用
性も良いことが判る。
<Examples 5 to 8> Creams were prepared according to the formulations shown in Table 3. That is, (a), (a), (c), and (d) were each dissolved or dispersed by heating at 80 ° C., (a) and (b) were kneaded, and this was diluted with (c), and (d) was gradually added and emulsified. This was stirred and cooled to obtain a cream. In addition, the results of observation when this was stored at 40 ° C. for 3 months are shown. It can be seen that the composition of the present invention has improved stability. The evaluation criteria were ++: marked, +: clearly observable, ±: slightly observed,-: not observed at all. The usability at 5 ° C. was also evaluated by a specialized panel. The results are shown in Table 3. It turns out that the composition of the present invention has good usability at low temperatures.

【0030】[0030]

【表3】 [Table 3]

【0031】<実施例9〜12>表4の処方に従って口
紅を作成した。即ち、アをボールミルで分散し、90℃
に加熱した。一方予め90℃に加熱溶解・分散しておい
たイを加え良く混合し型に流し込み、冷却し容器に装着
し口紅を作成した。併せて、このものを40℃に3カ月
保存した場合の観察結果を示した。本発明の組成物は安
定性を向上していることが判る。尚、評価基準は++:
著しい、+:明らかに観察できる、±:僅かに見られ
る、−:全く見られないであった。又、5℃における使
用性も専門パネラーにより評価してもらった。結果をあ
わせて表4に示す。本発明の組成物は低温での使用性も
良いことが判る。
<Examples 9 to 12> Lipsticks were prepared according to the formulations shown in Table 4. That is, a was dispersed in a ball mill, and 90 ° C.
Heated. On the other hand, a, which was previously heated and dissolved and dispersed at 90 ° C., was added, mixed well, poured into a mold, cooled, and mounted in a container to prepare a lipstick. In addition, the results of observation when this was stored at 40 ° C. for 3 months are shown. It can be seen that the composition of the present invention has improved stability. The evaluation criteria are ++:
Remarkable, +: clearly observable, ±: slightly observed,-: not observed at all. The usability at 5 ° C. was also evaluated by a specialized panel. The results are shown in Table 4. It turns out that the composition of the present invention has good usability at low temperatures.

【0032】[0032]

【表4】 [Table 4]

【0033】<実施例13〜16>下記表5の処方に従
って坐剤を作成した。即ち処方成分を加熱溶解分散さ
せ、型に流し込み冷却固化させて坐剤を得た。又、使用
性(下着の汚れと異物感)を専門パネラーにより判定し
てもらった。結果を表5に併せて記す。本発明の組成物
が使用感に優れることが判る。
<Examples 13 to 16> Suppositories were prepared according to the formulation shown in Table 5 below. That is, the prescription components were dissolved and dispersed by heating, poured into a mold, and cooled and solidified to obtain a suppository. In addition, usability (dirty underwear and foreign-body sensation) was determined by a specialized panelist. The results are also shown in Table 5. It turns out that the composition of the present invention is excellent in use feeling.

【0034】[0034]

【表5】 [Table 5]

【0035】<実施例17〜18>表6に示す処方に従
ってクリームを作成した。即ち、ア、イ、ウ、エをそれ
ぞれ80℃で加熱溶解又は分散し、アとイを混練りし、
これをウで希釈し、更にエを徐々に加え乳化した。これ
を攪拌冷却しクリームを得た。併せて、化粧料が茶碗な
どを汚すか否かについて、専門パネラーにより評価して
もらった。結果をあわせて表6に示す。本発明の組成物
は付着性が抑制されていることが判る。
<Examples 17 and 18> Creams were prepared according to the formulations shown in Table 6. That is, A, I, U, and D are each heated and dissolved or dispersed at 80 ° C., and A and B are kneaded,
This was diluted with c and further added gradually to emulsify. This was stirred and cooled to obtain a cream. At the same time, the panelists evaluated whether cosmetics stained tea bowls and the like. The results are shown in Table 6. It can be seen that the composition of the present invention has reduced adhesion.

【0036】[0036]

【表6】 [Table 6]

【0037】<実施例19〜22> 製造例 下記表7に従ってファンデーションを作成した。即ち、
イ、ロ、ハ、ニをそれぞれ秤リ、イを良く混練りし、ロ
を加えて希釈した後80℃に加熱した。これにニを分散
させ、更に、別途80℃に加熱したハを徐々に加え乳化
し、攪拌冷却してファンデーションを得た。このものを
40℃の恒温室に3カ月保存した場合の状態の変化をあ
わせて記す。尚、化合物1〜4を水に置換した対照例は
40℃2カ月で一部分離していた。これより本発明の組
成物であるファンデーションは、通常安定性が優れてい
るとされてきた対照例よりも、更に高温での安定性に優
れることが判る。
<Examples 19 to 22> Production Examples A foundation was prepared according to Table 7 below. That is,
A, B, C, and D were each weighed, and K was well kneaded, diluted by adding B, and then heated to 80 ° C. The mixture was dispersed therein, and the mixture was heated and gradually heated to 80 ° C., and emulsified. The mixture was stirred and cooled to obtain a foundation. The change in the state when this was stored in a constant temperature room at 40 ° C. for 3 months is also described. The control example in which Compounds 1 to 4 were replaced with water was partially separated at 40 ° C. for 2 months. This shows that the foundation, which is the composition of the present invention, is more excellent in stability at high temperatures than the control example, which is usually considered to be excellent in stability.

【0038】[0038]

【表7】 [Table 7]

【0039】<実施例23〜26> 配合例 下記表8に示す処方に従ってネイルカラーを作成した。
即ち、イをロに一様に分散・溶解させ、、これにハを攪
拌しながら加え均一に分散・溶解させ、予め混合・粉砕
しておいたニを加えて均一に分散させ容器に詰めネイル
カラーとした。尚、併せて40℃、3カ月の保存試験結
果も併せて記す。対照例は化合物1〜4をベントナイト
に置換した物を用いた。これらの結果より、本発明の組
成物であるネイルカラーは安定性に優れることが判る。
Examples 23 to 26 Formulation Examples Nail colors were prepared according to the formulations shown in Table 8 below.
That is, b is uniformly dispersed and dissolved in b, and c is added thereto with stirring to uniformly disperse and dissolve. Color. The results of the storage test at 40 ° C. for 3 months are also shown. As a control, compounds obtained by replacing compounds 1 to 4 with bentonite were used. From these results, it can be seen that the nail color which is the composition of the present invention has excellent stability.

【0040】[0040]

【表8】 [Table 8]

【0041】[0041]

【発明の効果】本発明によれば、安定性取り分け40℃
付近の体温における安定性と5〜10℃における使用性
に優れた医薬品、化粧品、食品等の組成物を提供するこ
とが可能である。
According to the present invention, the stability is particularly 40 ° C.
It is possible to provide a composition for pharmaceuticals, cosmetics, foods, and the like, which is excellent in stability at near body temperature and usability at 5 to 10 ° C.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 FI A61K 47/22 A61K 47/22 F C07D 239/22 C07D 239/22 (72)発明者 井柳 宏一 神奈川県横浜市戸塚区柏尾町560 ポーラ 化成工業株式会社戸塚研究所内────────────────────────────────────────────────── ─── Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 47/22 A61K 47/22 F C07D 239/22 C07D 239/22 (72) Inventor Koichi Iyanagi Kashio, Totsuka-ku, Yokohama-shi, Kanagawa Prefecture Town 560 Pola Kasei Kogyo Co., Ltd.

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 一般式(I)に表されるアスパラギン酸
フェニルアラニン環状ジペプタイド誘導体を含有する組
成物。 【化1】 一般式(I) (但し、Rは炭素数8〜22の環状構造を含むことので
きる直鎖又は分岐のアルキル基又はアルケニル基を表
す。)
1. A composition comprising a phenylalanine aspartate cyclic dipeptide derivative represented by the general formula (I). Embedded image General formula (I) (where R represents a linear or branched alkyl group or alkenyl group that can have a cyclic structure having 8 to 22 carbon atoms)
【請求項2】 アスパラギン酸フェニルアラニン環状ジ
ペプタイドの立体構造が、一般式(II)に示される
L、Lである、請求項1に記載の組成物。 【化2】 一般式(II) (但し、Rは炭素数8〜22の環状構造を含むことので
きる直鎖又は分岐のアルキル基又はアルケニル基を表
す。)
2. The composition according to claim 1, wherein the steric structure of the aspartic acid phenylalanine cyclic dipeptide is L or L represented by the general formula (II). Embedded image General formula (II) (where R represents a linear or branched alkyl group or alkenyl group that can have a cyclic structure having 8 to 22 carbon atoms)
【請求項3】 一般式(I)に表される化合物が、シク
ロ(L−β−ジメチルオクチルアスパラギニル−L−フ
ェニルアラニル)(化合物1)、シクロ(L−β−ラウ
リルアスパラギニル−L−フェニルアラニル)(化合物
2)又はシクロ(L−β−ステアリルアスパラギニル−
L−フェニルアラニル)(化合物3)である、請求項1
又は2に記載の組成物。 【化3】 化合物1 【化4】 化合物2 【化5】 化合物3
3. The compound represented by the general formula (I) is cyclo (L-β-dimethyloctylasparaginyl-L-phenylalanyl) (compound 1), cyclo (L-β-laurylasparaginyl) -L-phenylalanyl) (compound 2) or cyclo (L-β-stearylasparaginyl-
(L-phenylalanyl) (compound 3).
Or the composition according to 2. Embedded image Compound 1 Compound 2 Compound 3
【請求項4】 化粧料又は医薬である請求項1〜4に記
載の組成物。
4. The composition according to claim 1, which is a cosmetic or a medicine.
JP9049686A 1997-02-18 1997-02-18 Composition containing aspartic acid-phenylalanine cyclic dipeptide derivative Pending JPH10226615A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9049686A JPH10226615A (en) 1997-02-18 1997-02-18 Composition containing aspartic acid-phenylalanine cyclic dipeptide derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9049686A JPH10226615A (en) 1997-02-18 1997-02-18 Composition containing aspartic acid-phenylalanine cyclic dipeptide derivative

Publications (1)

Publication Number Publication Date
JPH10226615A true JPH10226615A (en) 1998-08-25

Family

ID=12838076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9049686A Pending JPH10226615A (en) 1997-02-18 1997-02-18 Composition containing aspartic acid-phenylalanine cyclic dipeptide derivative

Country Status (1)

Country Link
JP (1) JPH10226615A (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247451A (en) * 2000-03-06 2001-09-11 Pola Chem Ind Inc Gelled skin care preparation and method for producing polyhydric alcohol gel
WO2003059306A1 (en) * 2002-01-18 2003-07-24 Unilever Plc Cosmetic compositions comprising a cyclodipeptide compound
US6652843B2 (en) 2002-01-18 2003-11-25 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Antiperspirant compositions
JP2004518614A (en) * 2000-08-04 2004-06-24 ディーエムアイ バイオサイエンシズ インコーポレイテッド Method for using diketopiperazines and compositions containing diketopiperazines
JP2006525968A (en) * 2003-05-10 2006-11-16 ユニリーバー・ナームローゼ・ベンノートシヤープ Stick composition
JP2006328268A (en) * 2005-05-27 2006-12-07 Koei Chem Co Ltd Gel composition
EP2046778A1 (en) * 2006-08-04 2009-04-15 Manus Pharmaceuticals (Canada) Ltd. Multifunctional bioactive compounds
US8183209B2 (en) 2003-05-15 2012-05-22 Dmi Biosciences, Inc. Treatment of T-cell mediated diseases
US8217047B2 (en) 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
US8980834B2 (en) 2011-10-10 2015-03-17 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
US9034878B2 (en) 2010-09-07 2015-05-19 Ampio Pharmaceuticals, Inc. Treatment of diseases
US9808454B2 (en) 2013-03-15 2017-11-07 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
US9925300B2 (en) 2011-10-10 2018-03-27 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
US9956217B2 (en) 2014-08-18 2018-05-01 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US10881710B2 (en) 2011-10-28 2021-01-05 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247451A (en) * 2000-03-06 2001-09-11 Pola Chem Ind Inc Gelled skin care preparation and method for producing polyhydric alcohol gel
US8916568B2 (en) 2000-08-04 2014-12-23 Ampio Pharmaceuticals, Inc. Method of using diketopiperazines and composition containing them
US8268830B2 (en) 2000-08-04 2012-09-18 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US9561226B2 (en) 2000-08-04 2017-02-07 Ampio Pharmaceuticals, Inc. Method of using diketopiperazines and composition containing them
JP2004518614A (en) * 2000-08-04 2004-06-24 ディーエムアイ バイオサイエンシズ インコーポレイテッド Method for using diketopiperazines and compositions containing diketopiperazines
EP1311269A4 (en) * 2000-08-04 2006-05-17 Dmi Biosciences Inc Method of using diketopiperazines and composition containing them
US8455517B2 (en) * 2000-08-04 2013-06-04 Dmi Acquisition Corp. Method of using diketopiperazines and composition containing them
US10039760B2 (en) 2000-08-04 2018-08-07 Ampio Pharmaceuticals, Inc. Method of using diketopiperazines and composition containing them
US8841307B2 (en) 2000-08-04 2014-09-23 Ampio Pharmaceuticals, Inc. Method of using diketopiperazines and composition containing them
US6652843B2 (en) 2002-01-18 2003-11-25 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Antiperspirant compositions
US7332153B2 (en) 2002-01-18 2008-02-19 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Cosmetic compositions
WO2003059307A1 (en) * 2002-01-18 2003-07-24 Unilever Plc Cosmetic compositions comprising a cyclodipeptide compound
WO2003059306A1 (en) * 2002-01-18 2003-07-24 Unilever Plc Cosmetic compositions comprising a cyclodipeptide compound
JP2006525968A (en) * 2003-05-10 2006-11-16 ユニリーバー・ナームローゼ・ベンノートシヤープ Stick composition
US8324167B2 (en) 2003-05-15 2012-12-04 Dmi Biosciences, Inc. Treatment of T-cell mediated diseases
US8969308B2 (en) 2003-05-15 2015-03-03 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
US8183209B2 (en) 2003-05-15 2012-05-22 Dmi Biosciences, Inc. Treatment of T-cell mediated diseases
US9707227B2 (en) 2003-05-15 2017-07-18 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
US9730924B2 (en) 2003-05-15 2017-08-15 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
US11369598B2 (en) 2003-05-15 2022-06-28 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
US10828296B2 (en) 2003-05-15 2020-11-10 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
US8962568B2 (en) 2003-05-15 2015-02-24 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
JP2006328268A (en) * 2005-05-27 2006-12-07 Koei Chem Co Ltd Gel composition
US8637521B2 (en) 2006-08-04 2014-01-28 Manus Pharmaceuticals (Canada) Ltd. Substituted piperazin-2,5-diones and their use as multifunctional bioactive compounds
EP2046778A1 (en) * 2006-08-04 2009-04-15 Manus Pharmaceuticals (Canada) Ltd. Multifunctional bioactive compounds
AU2007280995B2 (en) * 2006-08-04 2012-05-03 Manus Pharmaceuticals (Canada) Ltd. Multifunctional bioactive compounds
AU2007280995C1 (en) * 2006-08-04 2013-05-23 Manus Pharmaceuticals (Canada) Ltd. Multifunctional bioactive compounds
US9108931B2 (en) 2006-08-04 2015-08-18 Manus Pharmaceuticals (Canada) Ltd. Substituted piperazin-2,5-diones as multifunctional bioactive compounds
EP2046778B1 (en) * 2006-08-04 2013-12-04 Manus Pharmaceuticals (Canada) Ltd. Multifunctional bioactive compounds
US8217047B2 (en) 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
US9522893B2 (en) 2008-05-27 2016-12-20 Ampio Pharmaceuticals, Inc. Therapeutic methods and compounds
US8871772B2 (en) 2008-05-27 2014-10-28 Ampio Pharmaceuticals, Inc. Therapeutic methods and compounds
US9034878B2 (en) 2010-09-07 2015-05-19 Ampio Pharmaceuticals, Inc. Treatment of diseases
US10842847B2 (en) 2011-10-10 2020-11-24 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
US9060968B2 (en) 2011-10-10 2015-06-23 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
US9925300B2 (en) 2011-10-10 2018-03-27 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
US11058798B2 (en) 2011-10-10 2021-07-13 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
US10251930B2 (en) 2011-10-10 2019-04-09 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
US9623072B2 (en) 2011-10-10 2017-04-18 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
US10471178B2 (en) 2011-10-10 2019-11-12 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
US8980834B2 (en) 2011-10-10 2015-03-17 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
US10881710B2 (en) 2011-10-28 2021-01-05 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
US11026940B2 (en) 2013-03-15 2021-06-08 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
US9808454B2 (en) 2013-03-15 2017-11-07 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
US10342793B2 (en) 2014-08-18 2019-07-09 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US9956217B2 (en) 2014-08-18 2018-05-01 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11090301B2 (en) 2014-08-18 2021-08-17 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases

Similar Documents

Publication Publication Date Title
JPH10226615A (en) Composition containing aspartic acid-phenylalanine cyclic dipeptide derivative
JP3894064B2 (en) Oil-based thickening gel composition, emulsified composition using the composition, and preparation method thereof
US20060067902A1 (en) Oil-in-water emulsion type cosmetic preparation
JP2007001994A (en) Cosmetic
JPH10237034A (en) Composition containing bis(acylamino)cyclohexane derivative
JPH10245315A (en) Composition containing cyclodipeptide derivative
JP2015067571A (en) Oil gel composition containing oil gelling agent, and oil gelling agent
JP5526121B2 (en) Oil gelling agent, oil gel composition containing the oil gelling agent, and skin external preparation or cosmetic containing the oil gel composition
JPH0570337A (en) Solid type water-in-oil type emulsified cosmetic
JP2006316003A (en) Stable liquid composition containing alcohol ester of hydrogenated rosin and cosmetic product containing the same
WO2004100918A1 (en) Oil-in-water emulsion cosmetics
JP3501612B2 (en) Composition containing cyclohexanetricarboxamide derivative
JP6353939B1 (en) Oily composition, process for producing the same, oily base and external preparation for skin
JPH09188605A (en) Makeup-removing agent
JPH10245396A (en) Composition containing alkylamide derivative of oligopeptide
JPH10231465A (en) Composition containing 1,3,5-tris((n-alkylamino) carbonyl)benzene
JPH10182500A (en) Medicine for external use and cosmetic
JP2854767B2 (en) Thickening gelling agent
JPH07304629A (en) Water-in-oil type emulsion composition and its production
JPH10245314A (en) Composition containing benzyloxycarbonylamino acid derivative
JPH10226614A (en) Isoleucine derivative-containing composition
JP2818887B2 (en) Gelling agent for oils
JP2006096703A (en) Sterol derivative
JPH08268877A (en) Water-and oil-repellent oil-in-water type emulsified composition
JPH0726244A (en) Thickening and gelling agent and thickened gel-like composition